Clinical Trial Update: Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 [Phase 1]

View source ↗

Summary

This Phase 1 safety and tolerability study of TAK-165 in patients with HER2-expressing tumors has completed, reporting on safety and tolerability across multipl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Kidney Cancer
• Lung Cancer
• Ovarian Cancer
• Pancreatic Cancer

Drugs mentioned

• TAK-165 (TAK-165)

Snippet

Sponsor: Takeda | Conditions: Breast Neoplasm, Pancreatic Neoplasm | Phase 1 | Status: COMPLETED